α-ketoheterocycle-based inhibitors of fatty acid amide hydrolase (FAAH)

ACS Chemical Neuroscience

Volumn 3, Issue 5, 2012, Pages 340-348

  Otrubova, Katerina ^a   Boger, Dale L ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

ketoheterocycles; FAAH; Fatty acid amide hydrolase; pain; sleep

Indexed keywords

7 PHENYL 1 [5 (2 PYRIDINYL) 2 OXAZOLYL] 1 HEPTANONE; ENZYME INHIBITOR; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; OLEAMIDE;

BINDING AFFINITY; CONFERENCE PAPER; CRYSTAL STRUCTURE; DRUG BINDING; DRUG DESIGN; DRUG EFFECT; DRUG STRUCTURE; HUMAN; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEOMICS; RETROSPECTIVE STUDY; X RAY;

EID: 84862075513     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn2001206     Document Type: Conference Paper

References (64)

1. Ezzili, C., Otrubova, K., and Boger, D. L. (2010) Fatty acid amide signaling molecules Bioorg. Med. Chem. Lett. 20, 5959-5968
2. Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., and Mechoulam, R. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258, 1946-1949 (Pubitemid 23026736)
3. Cravatt, B. F., Lerner, R. A., and Boger, D. L. (1996) Structure determination of an endogenous sleep-inducing lipid, cis-9-octadecenoamide (oleamide): a synthetic approach to the chemical analysis of trace quantities of a natural product J. Am. Chem. Soc. 118, 580-590 (Pubitemid 26054353)
4. Cravatt, B. F., Prospero-Garcia, O., Suizdak, G., Gilula, N. B., Henriksen, S. J., Boger, D. L., and Lerner, R. A. (1995) Chemical characterization of a family of brain lipids that induce sleep Science 268, 1506-1509
5. Lerner, R. A., Siuzdak, G., Prospero-Garcia, O., Henriksen, S. J., Boger, D. L., and Cravatt, B. F. (1994) Cerebrodiene: a brain lipid isolated from sleep-deprived cats Proc. Natl. Acad. Sci. U.S.A. 91, 9505-9508 (Pubitemid 24297943)
6. Boger, D. L., Henriksen, S. J., and Cravatt, B. F. (1998) Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules Curr. Pharm. Des. 4, 303-314 (Pubitemid 28398972)
7. Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., and Gilula, N. B. (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty acid amides Nature 384, 83-87 (Pubitemid 26374593)
8. Giang, D. K. and Cravatt, B. F. (1997) Molecular characterization of human and mouse fatty acid amide hydrolase Proc. Natl. Acad. Sci. U.S.A. 94, 2238-2242 (Pubitemid 27136858)
9. McKinney, M. K. and Cravatt, B. F. (2005) Structure and function of fatty acid amide hydrolase Annu. Rev. Biochem. 74, 411-432 (Pubitemid 40995513)
10. Egertova, M., Cravatt, B. F., and Elphick, M. R. (2003) Comparative analysis of fatty acid amide hydrolase and CB1 cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling Neuroscience 119, 481-496 (Pubitemid 36588826)
11. Long, J. Z., LaCava, M., Jin, X., and Cravatt, B. F. (2011) An anatomical and temporal portrait of physiological substrates for fatty acid amide hydrolase J. Lipid Res. 52, 337-344
12. Patricelli, M. P. and Cravatt, B. F. (2001) Characterization and manipulation of acyl chain selectivity of fatty acid amide hydrolase Biochemistry 40, 6107-6115 (Pubitemid 32466315)
13. Boger, D. L., Fecik, R. A., Patterson, J. E., Miyauchi, H., Patricelli, M. P., and Cravatt, B. F. (2000) Fatty acid amide hydrolase substrate specificity Bioorg. Med. Chem. Lett. 10, 2613-2616
14. Cravatt, B. F. and Lichtman, A. H. (2003) Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system Curr. Opin. Chem. Biol. 7, 469-775
15. Lambert, D. M. and Fowler, C. J. (2005) The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications J. Med. Chem. 48, 5059-5087 (Pubitemid 41113892)
16. Ahn, K., McKinney, M. K., and Cravatt, B. F. (2008) Enzymatic pathways that regulate endocannabinoid signaling in the nervous system Chem. Rev. 108, 1687-1707 (Pubitemid 351796405)
17. Ahn, K., Johnson, D. S., and Cravatt, B. F. (2009) Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders Exp. Opin. Drug Discovery 4, 763-784
18. Seierstad, M. and Breitenbucher, J. G. (2008) Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors J. Med. Chem. 51, 7327-7343
19. Deng, H. F. (2010) Fatty acid amide hydrolase as a therapeutic target Exp. Opin. Drug Discovery 5, 961-970
20. Otrubova, K., Ezzili, C., and Boger, D. L. (2011) The discovery and development of inhibitors of fatty acid amide hydrolase Bioorg. Med. Chem. Lett. 21, 4674-4685
21. Huitron-Resendiz, S., Gombart, L., Cravatt, B. F., and Henriksen, S. (2001) Effect of oleamide on sleep and its relationship to blood pressure, body temperature, and locomotor activity in rats J. Exp. Neurol. 172, 235-243 (Pubitemid 33141169)
22. Huitron-Resendiz, S., Sanchez-Alavez, M., Will, D. N., Cravatt, B. F., and Henriksen, S. J. (2004) Characterization of the sleep-wake patterns in mice lacking fatty acid amide hydrolase Sleep 27, 857-865 (Pubitemid 39095717)
23. 2 receptor mediated behavior in the rat by oleamide and the role of cannabinoid receptors Neuropharmacology 38, 533-541 (Pubitemid 29088231)
24. Leggett, J. D., Aspley, S., Beckett, S. R. G., D'Antona, A. M., and Kendall, D. A. (2004) Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors Br. J. Pharmacol. 141, 253-262 (Pubitemid 38250895)
25. Wilcox, B. J., Ritenour-Rodgers, K. J., Asser, A. S., Baumgart, L. E., Baumgart, M. A., Boger, D. L, Patterson, J. E., DeBlassio, J. L., deLong, M. A., Glufke, U., Henz, M. E., King, L., III, Merkler, K. A., Robleski, J. J., Vederas, J. C., and Merkler, D. J. (1999) N-Acylglycine amidation: implications for the biosynthesis of fatty acid primary amides Biochemistry 38, 3235-3245
26. 1A receptor potentiation by the biologically active lipid oleamide Proc. Natl. Acad. Sci. U.S.A. 95, 4102-4107
27. Boger, D. L., Patterson, J. E., Guan, X., Cravatt, B. F., Lerner, R. A., and Gilula, N. B. (1999) Chemical requirements for inhibition of gap junction communication by the biologically active lipid oleamide Proc. Natl. Acad. Sci. U.S.A. 95, 4810-4815 (Pubitemid 28208507)
28. Guan, X., Cravatt, B. F., Ehring, G. R., Hall, J. E., Boger, D. L., Lerner, R. A., and Gilula, N. B. (1997) The sleep-inducing lipid oleamide deconvolutes Gap junction communication and calcium wave transmission in glial cells J. Cell Biol. 139, 1785-1792 (Pubitemid 28079242)
29. Patricelli, M. P. and Cravatt, B. F. (1999) Fatty acid amide hyrolase degrades bioactive amides and esters through a nonconventional catalytic mechanism Biochemistry 38, 14125-14130
30. Patricelli, M. P. and Cravatt, B. F. (2000) Clarifying the catalytic roles of conserved residues in the amidase signature family J. Biol. Chem. 275, 19177-19184 (Pubitemid 30422888)
31. Patricelli, M. P., Lovato, M. A., and Cravatt, B. F. (1999) Chemical and mutagenic investigations of fatty acid amide hydrolase: evidence for a family of serine hydrolases with distinct catalytic properties Biochemistry 38, 9804-9812
32. McKinney, M. K. and Cravatt, B. F. (2003) Evidence for distinct roles in catalysis for residues of the serine-serine-lysine catalytic triad of fatty acid amide hydrolase J. Biol. Chem. 278, 37393-37399 (Pubitemid 37175258)
33. Bracey, M. H., Hanson, M. A., Masuda, K. R., Stevens, R. C., and Cravatt, B. F. (2002) Adaptations in a membrane enzyme that terminates endocannabinoid signaling Science 298, 1793-1796 (Pubitemid 35404124)
34. Yanagisawa, I. and Yoshikawa, H. (1973) A bromine compound isolated from human cerebrospinal fluid Biochim. Biophys. Acta 329, 283-294
35. Patricelli, M. P., Patterson, J. P., Boger, D. L., and Cravatt, B. F. (1998) An endogenous REM sleep inducing compound is a potent competitive inhibitor of fatty acid amide hydrolase (FAAH) Bioorg. Med. Chem. Lett. 8, 613-618 (Pubitemid 28122362)
36. Patterson, J. E., Ollmann, I. R., Cravatt, B. F., Boger, D. L., Wong, C.-H., and Lerner, R. A. (1996) Inhibition of oleamide hydrolase catalyzed hydrolysis of the endogenous sleep-inducing lipid: cis-9-octadecenamide J. Am. Chem. Soc. 118, 5938-5945 (Pubitemid 26236814)
37. Koutek, B., Prestwich, G. D., Howlett, A. C., Chin, S. A., Salehani, D., Akhavan, N., and Deutsch, D. G. (1994) Inhibitors of arachidonoyl ethanolamide hydrolysis J. Biol. Chem. 269, 22937-22940 (Pubitemid 24283267)
38. Boger, D. L., Sato, H., Lerner, A. E., Austin, B. J., Patterson, J. E., Patricelli, M. P., and Cravatt, B. F. (1999) Trifluoromethyl ketone inhibitors of fatty acid amide hydrolase: a probe of structural and conformational features contributing to inhibition Bioorg. Med. Chem. Lett. 9, 265-270 (Pubitemid 29059542)
39. Edwards, P. D., Meyer, E. F. J., Vijayalakshmi, J., Tuthill, P. A., Andisik, D. A., Gomes, B., and Strimpler, A. (1992) Design, synthesis, and kinetic evaluation of a unique class of elastase inhibitors, the peptidyl α-ketooxazoles, the x-ray crystal structure of the covalent complex between porcine pancreatic elastase and Ac-Ala-Pro-Val-2-benzoxazole J. Am. Chem. Soc. 114, 1854-1863
40. Boger, D. L., Sato, H., Lerner, A. E., Hedrick, M. P., Fecik, R. A., Miyauchi, H., Wilkie, G. D., Austin, B. J., Patricelli, M. P., and Cravatt, B. F. (2000) Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide Proc. Natl. Acad. Sci. U.S.A. 97, 5044-5049 (Pubitemid 30313668)
41. Boger, D. L., Miyauchi, H., and Hedrick, M. P. (2001) α-Keto heterocycle inhibitors of fatty acid amide hydrolase: carbonyl group modification and α-substitution Bioorg. Med. Chem. Lett. 11, 1517-1520 (Pubitemid 32703554)
42. Leung, D., Du, W., Hardouin, C., Cheng, H., Hwang, I., Cravatt, B. F., and Boger, D. L. (2005) Discovery of an exceptionally potent and selective class of fatty acid amide hydrolase inhibitors enlisting proteome-wide selectivity screening: concurrent optimization of enzyme inhibitor potency and selectivity Bioorg. Med. Chem. Lett. 15, 1423-1428 (Pubitemid 40269005)
43. Liu, Y., Patricelli, M. P., and Cravatt, B. F. (1999) Activity-based protein profiling: the serine hydrolases Proc. Natl. Acad. Sci. U.S.A. 96, 14694-14699 (Pubitemid 30019702)
44. Patricelli, M. P., Giang, D. K., Stamp, L. M., and Burbaum, J. J. (2001) Direct visualization of serine hydrolase activities in complex proteomes using fluorescent active site-directed probes Proteomics 1, 1067-1071 (Pubitemid 33696471)
45. Kidd, D., Liu, Y., and Cravatt, B. F. (2001) Profiling serine hydrolase activity in complex proteomes Biochemistry 40, 4005-4015 (Pubitemid 32280438)
46. Leung, D., Hardouin, C., Boger, D. L., and Cravatt, B. F. (2003) Discovering potent and selective reversible inhibitors of enzymes in complex proteomes Nat. Biotechnol. 21, 687-691 (Pubitemid 36638097)
47. Boger, D. L., Miyauchi, H., Du, W., Hardouin, C., Fecik, R. A., Cheng, H., Hwang, I., Hedrick, M. P., Leung, D., Acevedo, O., Guimaráes, C. R. W., Jorgensen, W. L., and Cravatt, B. F. (2005) Discovery of a potent, selective, and efficacious class of reversible α-ketoheterocycle inhibitors of fatty acid amide hydrolase as analgesics J. Med. Chem. 48, 1849-1856 (Pubitemid 40396316)
48. Lichtman, A. H., Leung, D., Shelton, C. C., Saghatelian, A., Hardouin, C., Boger, D. L., and Cravatt, B. F. (2004) Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity J. Pharmacol. Exp. Ther. 311, 441-448 (Pubitemid 39391527)
49. Romero, F. A., Hwang, I., and Boger, D. L. (2006) Delineation of a fundamental α-ketoheterocycle substituent effect for use in the design of enzyme inhibitors J. Am. Chem. Soc. 68, 14004-14005 (Pubitemid 44657474)
50. Chang, L., Luo, L., Palmer, J. A., Sutton, S., Wilson, S. J., Barbier, A. J., Breitenbucher, J. G., Chaplan, S. R., and Webb, M. (2006) Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms Br. J. Pharmacol. 148, 102-113 (Pubitemid 43675605)
51. Kinsey, S. G., Long, J. Z., O'Neal, S. T., Abdulla, R. A., Poklis, J. L., Boger, D. L., Cravatt, B. F., and Lichtman, A. H. (2009) Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain J. Pharmacol. Exp. Ther. 330, 902-910
52. Schlosburg, J. E., Boger, D. L., Cravatt, B. F., and Lichtman, A. H. (2009) Endocannabinoid modulation of scratching response in an acute allergenic model: new prospective neural therapeutic target for pruritus J. Pharmacol. Exp. Ther. 329, 314-323
53. Booker, L., Kinsey, S. G., Abdullah, R. A., Blankman, J. L., Long., J. Z., Ezzili, C., Boger, D. L., Cravatt, B. F., and Lichtman, A. H. The FAAH inhibitor PF-3845 acts in the nervous system to reverse lipopolysaccharide- induced tactile allodynia in mice. Br. J. Pharmacol. 2011, in press.
54. Romero, F. A., Du, W., Hwang, I., Rayl, T. J., Kimball, F. S., Leung, D., Hoover, H. S., Apodaca, R. L., Breitenbucher, J. G., Cravatt, B. F., and Boger, D. L. (2007) Potent and selective α-ketoheterocycle-based inhibitors of the anandamide and oleamide catabolizing enzyme, fatty acid amide hydrolase J. Med. Chem. 50, 1058-1068 (Pubitemid 46394008)
55. DeMartino, J. K., Garfunkle, J., Hochstatter, D. G., Cravatt, B. F., and Boger, D. L. (2008) Exploration of a fundamental substituent effect of α-ketoheterocycle enzyme inhibitors: potent and selective inhibitors of fatty acid amide hydrolase Bioorg. Med. Chem. Lett. 18, 5842-5846
56. Hardouin, C., Kelso, M. J., Romero, F. A., Rayl, T. J., Leung, D., Hwang, I., Cravatt, B. F., and Boger, D. L. (2007) Structure-activity relationships of α-ketooxazole inhibitors of fatty acid amide hydrolase J. Med. Chem. 50, 3359-3368 (Pubitemid 47065985)
57. Kimball, F. S., Romero, F. A., Ezzili, C., Garfunkle, J., Rayl, T. J., Hochstatter, D. G., Hwang, I., and Boger, D. L. (2008) Optimization of α-ketooxazole inhibitors of fatty acid amide hydrolase J. Med. Chem. 51, 937-947 (Pubitemid 351304701)
58. Garfunkle, J., Ezzili, C., Rayl, T. J., Hochstatter, D. G., Hwang, I., and Boger, D. L. (2008) Optimization of the central heterocycle of α-ketoheterocycle inhibitors of fatty acid amide hydrolase J. Med. Chem. 51, 4393-4403
59. Guimaráes, C. R. W., Boger, D. L., and Jorgensen, W. L. (2005) Elucidation of fatty acid amide hydrolase inhibition by potent α-ketoheterocycle derivatives from Monte Carlo simulations J. Am. Chem. Soc. 127, 17377-17384 (Pubitemid 41791056)
60. Slaymaker, I. M., Bracey, M., Mileni, M., Garfunkle, J., Cravatt, B. F., Boger, D. L., and Stevens, R. C. (2008) Correlation of inhibitor effects on enzyme activity and thermal stability for integral membrane protein fatty acid amide hydrolase Bioorg. Med. Chem. Lett. 18, 5847-5850
61. Ezzili, C., Mileni, M., McGlinchey, N., Long, J. Z., Kinsey, S. G., Hochstatter, D. G., Stevens, R. C., Lichtman, A. H., Cravatt, B. F., Bilsky, E. J., and Boger, D. L. (2011) Reversible competitive α-ketoheterocycle inhibitors of fatty acid amide hydrolase containing additional conformational constraints in the acyl side chain: orally active, long acting analgesics J. Med. Chem. 54, 2805-2822
62. Mileni, M., Garfunkle, J., DeMartino, J. K., Cravatt, B. F., Boger, D. L., and Stevens, R. C. (2009) Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by α-ketoheterocycle inhibitors revealed from cocrystal structures J. Am. Chem. Soc. 131, 10497-10506
63. Mileni, M., Garfunkle, J., Ezzili, C., Kimball, F. S., Cravatt, B. F., Stevens, R. C., and Boger, D. L. (2010) X-ray crystallographic analysis of α-ketoheterocycle inhibitors bound to a humanized variant of fatty acid amide hydrolase J. Med. Chem. 53, 230-240
64. Mileni, M., Garfunkle, J., Ezzili, C., Cravatt, B. F., Stevens, R, C., and Boger, D. L. (2011) Fluoride-mediated capture of a noncovalent bound state of a reversible covalent enzyme inhibitor: X-ray crystallographic analysis of an exceptionally potent α-ketoheterocycle inhibitor of fatty acid amide hydrolase J. Am. Chem. Soc. 133, 4092-4100